Serum biomarker profiling in cancer studies: A question of standardisation?

Veterinary and Comparative Oncology

Volumn 6, Issue 4, 2008, Pages 224-247

  Matharoo Ball, B ^a   Miles, A K ^a   Creaser, C S ^b   Ball, G ^a   Rees, Robert ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

Biomarker; Clinical proteomics; MALDI MS; Mass spectrometry; Protein analysis; Protein marker discovery

Indexed keywords

ANIMALIA;

TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; BLOOD; CAT; CAT DISEASE; DOG; DOG DISEASE; NEOPLASM; REVIEW; STANDARD;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; NEOPLASMS; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL;

EID: 63849283060     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2008.00171.x     Document Type: Review

References (102)

1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S and Winn RJ. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. Journal Nationl Cancer Institute 1996; 88: 1456-1466.
2. Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J and Brünner N. European Organisation for Research and Treatment of Cancer (EORTC) Receptor and Biomarker Group. Tumor markers: From laboratory to clinical utility. Molecular & Cellular Proteomics 2003; 2: 378-387.
3. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology 2005; 99: 267-277.
4. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, Clarke-Pearson DL, Rodriguez G, Oram DH and Bast RC Jr. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecologic Oncology 1995; 59: 111-116.
5. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR and Bast RC Jr. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecologic Oncology 1999; 73: 56-61.
6. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L and Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Laboratory Investigation 2008; 88: 342-353.
7. Traverso LW The state of the highest level of evidence: An overview of systematic reviews of pancreaticobiliary disease customized for the gastroenterologist and GI surgeon. Journal of Gastrointestinal Surgery 2008; 12: 617-619.
8. Lips EH, van Eijk R, de Graaf EJ, Doornebosch PG, de Miranda NF, Oosting J, Karsten T, Eilers PH, Tollenaar RA, van Wezel T and Morreau H. Progression and tumor heterogeneity analysis in early rectal cancer. Clinical Cancer Research 2008; 14: 772-781.
9. Liotta LA, Kohn EC and Petricoin EF. Clinical proteomics: Personalised molecular medicine. The Journal of the American Medical Association 2001; 286: 2211-2214.
10. Marshall T and Williams KM. Proteomics and its impact upon biomedical science. British Journal Biomedical Science 2002; 591: 47-64.
11. Jain KK. Personalised medicine. Current Opinion in Molecular Therapeutics 2002; 4: 548-558.
12. de Freitas Campos C, Cole N, Dyk DV, Walsh BJ, Diakos P, Almeida D, Torrecilhas A, Laus JL and Willcox MD. Proteomic analysis of dog tears for potential cancer markers. Research in Veterinary Science 2008; 85: 349-352.
13. McCaw DL, Chan AS, Stegner AL, Mooney B, Bryan JN, Turnquist SE, Henry CJ, Alexander H and Alexander S. Proteomics of canine lymphoma identifies potential cancer-specific protein markers. Clinical Cancer Research 2007; 13: 2496-2503.
14. Gaines PJ, Powell TD, Walmsley SJ, Estredge KL, Wisnewski N, Stinchcomb DT, Withrow SJ and Lana SE. Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry. American Journal of Veterinary Research 2007; 68: 405-410.
15. McNiel EA, Carmella SG, Heath LA, Bliss RL, Le KA and Hecht SS. Urinary biomarkers to assess exposure of cats to environmental tobacco smoke. American Journal of Veterinary Research 2007; 68: 349-353.
16. Petricoin, EF, Ardekani, AM, Hitt, BA, Levine, PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC and Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 16: 572-577.
17. Alaoui-Jamali MA and Xu YJ. Proteomic technology for biomarker profiling in cancer: An update. Journal of Zhejiang University Science B 2006; 7: 411-420.
18. Traum AZ and Schachter AD. Transplantation proteomics. Pediatric Transplantation 2005; 9: 700-711.
19. Merril CR, Switzer RC and Van Keuren ML. Trace polypeptides in cellular extracts and human body fluids detected by two dimensional electrophoresis and a highly sensitive silver stain. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 4335-4339.
20. Patton WF. A thousand points of light: The application of fluorescence detection technologies to two-dimensional gel electrophoresis and proteomics. Electrophoresis 2000; 21: 1123-1144.
21. Lopez MF. 2-D electrophoresis using carrier ampholytes in the first dimension (IEF). Methods in Molecular Biology 1999; 112: 111-127.
22. Gygi SP, Corthals GL, Zhang Y, Rochon Y and Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proceedings of the National Academy of Sciences of the United States of America 2000; 97: 9390-9395.
23. Lilley KS, Razzaq A and Dupree P. Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Current Opinion in Chemical Biology 2002; 6: 46-50.
24. Timperman AT and Aebersold R. Peptide electroextraction for direct coupling of in-gel digests with capillary LC-MS/MS for protein identification and sequencing. Analytical Chemistry 2000; 72: 4115-4121.
25. Unlu M, Morgan ME and Minden JS. Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 1997; 18: 2071-2077.
26. Okuzawa K, Franzen B, Lindholm J, Linder S, Hirano T, Bergman T, Ebihara Y, Kato H and Auer G. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1994; 15: 382-390.
27. Lin JD, Huang CC, Weng HF, Chen SC and Jeng LB. Comparison of membrane proteins from benign and malignant human thyroid tissues by two-dimensional polyacrylamide gel electrophoresis. Journal of Chromatography. B, Biomedical Application 1995; 667: 153-160.
28. Ward LD, Hong J, Whitehead RH, Simpson RJ. Development of a database of amino acid sequences for human colon carcinoma proteins separated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1990; 11: 883-891.
29. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, Wilkins MR, Doro G, Cappellano F, Hughes G, Hochstrasser DF and Mocarelli P. Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997; 18: 599-604.
30. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Orntoft TF and Rasmussen HH. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Research 1996; 56: 4782-4790.
31. O'Farrell PZ and Gold LM. Transcription and translation of prereplicative bacteriophage T4 genes in vitro. Journal of Biological Chemistry 1973; 248: 5512-5519.
32. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK and Kuerer HM. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006; 6: 68-77.
33. Kennedy S. The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 2002; 7: 269-290.
34. LoPachin RM, Jones RC, Patterson TA, Slikker W Jr and Barber DS. Application of proteomics to the study of molecular mechanisms in neurotoxicology. Neurotoxicology 2003; 24: 761-775.
35. Haqqani AS, Hutchison JS, Ward R and Stanimirovic DB. Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS. Journal of Neurotrauma 2007; 24: 54-74.
36. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z and Wright GL Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 2002; 62: 3609-3614.
37. Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine RJ, Linghan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 2002 94: 1576-1578.
38. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S and Wright GL Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. American Journal of Pathology 2001; 158: 1491-1502.
39. Balls GR, Sanders GE and Palmer-Brown D. Investigating microclimatic influences on ozone injury in clover (Trifolium subterraneum L. cv. Geraldton) using artificial neural networks. The New Phytologist 1996; 132: 271-280.
40. Mian S, Ball G, Hornbuckle J, Holding F, Carmichael J, Ellis I, Ali S, Li G, McArdle S, Creaser C and Rees R. A prototype methodology combining surface-enhanced laser desorption/ionisation protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to paclitaxel and doxorubicin under in vitro conditions. Proteomics 2003; 9: 1725-1737.
41. Matharoo-Ball B, Ratcliff L, Lancashire L, Ugurel S, Miles AK, Weston DJ, Rees R, Schadendorf D, Ball G and Creaser CS. Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TPF mass spectrometry/bioinformatic approach. Proteomics Clinical Applications 2007; 1: 605-620.
42. Stoeckli M, Chaurand P, Hallahan DE and Caprioli RM. Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Natural Medicine 2001; 7: 493-496.
43. Xu BJ, Caprioli RM, Sanders ME and Jensen RA. Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. Journal of the American Society for Mass Spectrometry 2002; 13: 1292-1297.
44. Veenstra TD, Prieto DA and Conrads TP. Proteomic patterns for early cancer detection. Drug Discovery Today 2004; 9: 889-897.
45. Kaufmann R, Spengler B and Lutzenkirchen F. Mass spectrometric sequencing of linear peptides by product-ion analysis in a reflectron time-of-flight mass spectrometer using matrix-assisted laser desorption ionisation. Rapid Communications in Mass Spectrometry 1993; 7: 902-910.
46. Spengler B, Kirsch D and Kaufmann R. Peptide sequencing by matrix-assisted laser-desorption mass spectrometry. Rapid Communications in Mass Spectrometry 1992; 6: 105-108.
47. Hutchens TW and Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Communications in Mass Spectrometry 1993; 7: 576-580.
48. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clinical Chemistry 2002; 48: 1296-1304.
49. Wright GW Jr, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L and Vlahou A. Proteinchip(R) surface enhanced laser desorption/ionisation (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer and Prostatic Diseases 1999; 2: 264-276.
50. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R and Schadendorf D. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. Journal of Clinical Oncology 2005; 23: 5088-5093.
51. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP and Veenstra TD. Characterization of the low molecular weight human serum proteome. Molecular & Cellular Proteomics 2003; 2: 1096-1103.
52. Harper RG, Workman SR, Schuetzner S, Timperman AT and Sutton JN. Low-molecular-weight human serum proteome using ultrafiltration, isoelectric focusing, and mass spectrometry. Electrophoresis 2004; 25: 1299-1306.
53. Koomen JM, Zhao H, Li D, Nasser W, Hawke DH, Abbruzzese JL, Baggerly KA and Kobayashi R. Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. Rapid Communications in Mass Spectrometry 2005; 19: 1624-1636.
54. Arneberg R, Rajalahti T, Flikka K, Berven FS, Kroksveen AC, Berle M, Myhr KM, Vedeler CA, Ulvik RJA and Kvalheim OM. Pretreatment of mass spectral profiles: Application to proteomic data. Analytical Chemistry 2007; 79: 7014-7026.
55. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. Molecular & Cellular Proteomics 2004; 3: 367-378.
56. Wong JW, Cagney G and Cartwright HM. SpecAlign - processing and alignment of mass spectra datasets. Bioinformatics 2005; 21: 2088-2090.
57. Bishop C. Neural Networks for Pattern Recognition, New York, Oxford University Press, 1995.
58. Michiels S, Koscielny S and Hill C. Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 2005; 365: 488-492.
59. Sorace JM and Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003; 9: 24.
60. Check E. Proteomics and cancer: Running before we can walk? Nature 2004; 429: 496-497.
61. Baggerly KA, Morris JS and Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments. Bioinformatics 2004; 22: 777-85.
62. DeSouza LV, Grigull J, Ghanny S, Dube V, Romaschin AD, Colgan TJ and Siu KW. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Molecular & Cellular Proteomics 2007; 6: 1170-1182.
63. Chen R, Brentnall TA, Pan S, Cooke K, White Moyes K, Crispin DA, Goodlett DR, Aebersold R and Bronner MP. Quantitative proteomic analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Molecular & Cellular Proteomics 2007; 6: 1331-1342.
64. Comuzzi B and Sadar MD. Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer. Cellscience 2006; 3: 61-81.
65. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH and Montine TJ. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimers Disease 2005; 7: 125-133.
66. Montine TJ, Woltjer RL, Pan C, Montine KS and Zhang J. Liquid chromatography with tandem mass spectrometry-based proteomic discovery in aging and Alzheimer's disease. NeuroRx 2006; 3: 336-343.
67. Rossignol M, Peltier JB, Mock HP, Matros A, Maldonado AM and Jorrin JV. Plant proteome analysis: A 2004-2006 update. Proteomics 2006; 6: 5529-5548.
68. Jorrin JV, Maldonado AM and Castillejo MA. Plant proteome analysis: A 2006 update. Proteomics 2007; 7: 2947-2962.
69. Gluckmann M, Fella K, Waidelich D, Merkel D, Kruft V, Kramer PJ, Walter Y, Hellmann J, Karas M and Kröger M. Prevalidation of potential protein biomarkers in toxicology using iTRAQ reagent technology. Proteomics 2007; 7: 1564-1574.
70. Kristiansson MH, Bhat VB, Babu IR, Wishnok JS and Tannenbaum SR. Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice. Journal of Proteome Research 2007; 6: 1735-1744.
71. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ and Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimers Disease 2006; 9: 293-348.
72. Salim K, Kehoe L, Minkoff MS, Bilsland JG, Munoz-Sanjuan I and Guest PC. Identification of differentiating neural progenitor cell markers using shotgun isobaric tagging mass spectrometry. Stem Cells and Development 2006; 15: 461-470.
73. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A and Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular & Cellular Proteomics 2004; 3: 1154-1169.
74. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. Journal of Experimental Botany 2006; 57: 1501-1508.
75. Wu WW, Wang G, Baek SJ and Shen RF. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. Journal of Proteome Research 2006; 5: 651-658.
76. Graves PR and Haystead TA. Molecular biologist's guide to proteomics. Microbiology and Molecular Biology Reviews 2002; 66: 39-63.
77. Cooks RGGG, McLuckey SA and Kaiser RE. Ion trap mass spectrometry. Chemical Engineering News 1991; 25: 26-41.
78. Liebler DC. Introduction to Proteomics: Tools for the New Biology, 2nd edn., Totowa, Humana Press, 2002.
79. Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003; 13: 457-470.
80. Sullivan B, Addona TA and Carr SA. Selective detection of glycopeptides on ion trap mass spectrometers. Analytical Chemistry 2004; 76: 3112-3118.
81. Cutalo JM, Deterding LJ and Tomer KB. Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. Journal of the American Society for Mass Spectrometry 2004; 15: 1545-1555.
82. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zhax XM, Polakienicz RD, Comb MJ. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nature Biotechnology 2005; 23: 94-101.
83. Pinkse MW, Uitto PM, Hilhorst MJ, Ooms B and Heck AJ. Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Analytical Chemistry 2004; 76: 3935-3943.
84. Nagele E, Vollmer M and Horth P. Improved 2D nano-LC/MS for proteomics applications: A comparative analysis using yeast proteome. Journal of Bimolecular Technique 2004; 15: 134-143.
85. Nagele E, Vollmer M and Horth P. Two-dimensional nano-liquid chromatography-mass spectrometry system for applications in proteomics. Journal of Chromatography. A 2003; 1009: 197-205.
86. Wagner Y, Sickmann A, Meyer HE and Daum G. Multidimensional nano-HPLC for analysis of protein complexes. Journal of the American Society for Mass Spectrometry 2003; 14: 1003-1011.
87. Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, Elcasim M, Rees R, Layfield R, Atiomo W. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. Journal of Proteome Research 2007; 6: 3321-3328.
88. Barker, PE, Wagner PD, Stein SE, Bunk DM, Srivastava S and Omenn GS. Standards for plasma and serum proteomics in early cancer detection: A needs assessment report from the national institute of standards and technology - National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August. Clinical Chemistry 2006; 52: 1669-1674.
89. Prakash A, Piening B, Whiteaker J, Zhang H, Shaffer SA, Martin D, Hohmann L, Cooke K, Olson JM, Hansen S, Flory MR, Lee H, Watts J, Goodlett DR, Aebersold R, Paulovich A and Schwikowski B. Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics. Molecular & Cellular Proteomics 2007; 6: 1741-1748.
90. Kreunin P, Urquidi V, Lubman DM and Goodison S. Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 2004; 4: 2754-2765.
91. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET and Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research 2004; 64: 5882-5890.
92. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ and Stock RG. Putative protein markers in the sera of men with prostatic neoplasms. BJU International 2003; 92: 223-225.
93. Hanash S, Brichory F and Beer D. A proteomic approach to the identification of lung cancer markers. Disease Markers 2001; 17: 295-300.
94. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC and Petricoin EF III. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2: 76-84.
95. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD and Caprioli RM. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionisation mass spectrometry. Cancer Research. 2005; 65: 7674-7681.
96. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr and Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. Journal of the National Cancer Institute 2007; 99: 838-846.
97. Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL and Caprioli RM. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Research 2004; 64: 9093-9100.
98. Skalnikova H, Halada P, Dzubak P, Hajduch M and Kovarova H. Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: Identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry. Technology in Cancer Research & Treatment 2005; 4: 447-454.
99. Moseley MA. Current trends in differential expression proteomics: isotopically coded tags. Trends in Biotechnology 2001; 19: S10-S6.
100. MacCoss MJ and Yates JR III. Proteomics: Analytical tools and techniques. Current Opinion in Clinical Nutrition and Metabolic Care 2001; 4: 369-375.
101. Li S and Zeng D. CILAT - a new reagent for quantitative proteomics. Chemical Communication (Cambridge, England) 2007; 21: 2181-2183.
102. Smolka MB, Zhou H, Purkayastha S and Aebersold R. Optimization of the isotope-coded affinity tag-labelling procedure for quantitative proteome analysis. Analytical Biochemistry 2001; 297: 25-31.